


# Oxidant-Dependent Chemoselectivity in the Gold-Catalyzed Oxidative Cyclizations of 3,4,6,6-Tetrasubstituted 3,5-Dien-1-yne

Hsiao-Hua Hung, Yi-Ching Liao, and Rai-Shung Liu\*

Department of Chemistry, National Tsing-Hua University, Hsinchu, Taiwan, ROC


**S** Supporting Information

**ABSTRACT:** A distinct chemoselectivity in the gold-catalyzed oxidative cyclization of 3,5-dien-1-yne was observed when 3,5-dichloropyridine *N*-oxide replaced 8-methylquinoline *N*-oxide as the oxidant; the resulting cyclopentadienyl aldehydes were obtained in good yields. The altered chemoselectivity is attributed to a prior enyne cyclization in the presence of 3,5-dichloropyridine *N*-oxides. The use of *N*-iminopyridium ylide enables a similar iminocyclization reaction to give cyclopentadienyl imines efficiently. Our experimental data support a prior gold-catalyzed cyclization of 3,5-dien-1-yne to form gold carbene, followed by the oxidation with *N*-oxide.



## INTRODUCTION

Gold-catalyzed intermolecular oxidation of terminal alkynes with pyridine-based oxides is a powerful tool to access  $\alpha$ -functionalized carbonyl compounds (eq 1).<sup>1–3</sup> This oxidation




involves an initial attack of *N*-oxides at the alkynyl C(2)-carbon to generate  $\alpha$ -oxo gold carbenes **I** that are trapped *in situ* with a suitable substrate (**S**).<sup>1,2</sup> The chemoselectivity in this alkyne oxidation is generally invariant with diverse derivatives of pyridine-based oxides. We are aware of no report in which the reaction chemoselectivity varied with a change of *N*-oxide. In this work, we report a distinct chemoselectivity in the oxidative cyclization of 3,5-dien-1-yne with alterable pyridine-based *N*-oxides.


Shown in Scheme 1 is the oxidant-dependent chemoselectivity. We reported that gold-catalyzed reactions between

## Scheme 1. Two Distinct Oxidative Cyclizations

Previous report:



This work:



[Au] = IPrAuCl/AgNTf<sub>2</sub>


3,5-dien-1-yne and 8-methylquinoline *N*-oxide (8-MQO) resulted in an oxidative cyclopropanation with high stereospecificity;<sup>2b</sup> this process involves  $\alpha$ -oxo gold carbenes as intermediates.<sup>1,2</sup> Herein, we report the use of 3,5-dichloropyridine *N*-oxide in the reactions to give cyclopentadienyl aldehydes **3** instead and present experimental results to clarify the reaction mechanisms.

## RESULTS AND DISCUSSION

Table 1 (entry 1) shows our previously reported reaction between dienyne **1a**, IPrAuCl/AgNTf<sub>2</sub> (5 mol %, IPr = 1,3-bis(diisopropylphenyl)imidazol-2-ylidene), and 8-methylquinoline *N*-oxide (8-MQO, 1.2 equiv) in hot DCE (80 °C, 0.33 h), resulting in an oxidative cyclopropanation product **2a** in 60% yield.<sup>2b</sup> The yield was increased to 78% using the same *N*-oxidant in a large proportion (3 equiv). We tested the reactions with alterable pyridine-based *N*-oxides; Brønsted acids were excluded here to avoid the polymerization of starting **1a**. With pyridine *N*-oxide and its 2-ethyl derivative (1.2 equiv) in hot DCE (80 °C, 24–48 h), we obtained a new compound, cyclopentadienyl aldehyde **3a**, in low yield (<35%) together with indanone **2a** and unreacted **1a** in a substantial proportions (>18%, entries 2 and 3). The yields of aldehyde **3a** were enhanced to 56–60% yields with electron-deficient pyridine *N*-oxides bearing a chloro or bromo substituent at the C(2)- or C(3)-carbons (entries 4–6). To our pleasure, the use of 3,5-dichloropyridine *N*-oxide in hot DCE (80 °C, 0.33 h) effected a complete suppression of cyclopropyl indanone **2a** to deliver compound **3a** with 83% yield (entry 7). IPrAuCl/AgSbF<sub>6</sub> also maintained a high efficiency to give aldehyde **3a** in 76% yield (entry 9). P(*t*-Bu)<sub>2</sub>(*o*-biphenyl)AuCl/AgNTf<sub>2</sub> and PPh<sub>3</sub>AuCl/AgNTf<sub>2</sub> were less chemoselective in giving compound **3a** in less yield together with undesired **2a** in 16–22% yields (entries 10

Received: May 28, 2013

Published: July 22, 2013


Table 1. Reactions with Various *N*-Oxides and Gold Catalysts











entry	catalyst <sup>a</sup> (mol %)	<i>N</i> -oxide <sup>b</sup>	°C/h	compounds (yields) <sup>c</sup>		
				1a	2a	3a
1	IPrAuCl/AgNTf <sub>2</sub>	8-MQO	80/0.3		60 (78) <sup>d</sup>	
2	IPrAuCl/AgNTf <sub>2</sub>	R = H	80/48	59	24	6
3	IPrAuCl/AgNTf <sub>2</sub>	R = 2-Et	80/24	25	35	18
4	IPrAuCl/AgNTf <sub>2</sub>	R = 2-Br	80/0.7		24	60
5	IPrAuCVAgNTf <sub>2</sub>	R = 3-Br	80/0.2		26	57
6	IPrAuCyAgNTf <sub>2</sub>	R = 2-Cl	80/0.3		30	56
7	IPrAuCl/AgNTf <sub>2</sub>	R = 3,5-Cl <sub>2</sub>	80/0.3			83
8	IPrAuCVAgNTf <sub>2</sub>	R = 3,5-Cl <sub>2</sub>	25/0.6			81
9	IPrAuCl/AgSbF <sub>6</sub>	R = 3,5-Cl <sub>2</sub>	25/0.8			76
10	LAuCl/AgNTf <sub>2</sub>	R = 3,5-Cl <sub>2</sub>	25/1.0		22	57
11	PPh <sub>3</sub> AuCl/AgNTf <sub>2</sub>	R = 3,5-Cl <sub>2</sub>	25/1.2		16	56
12	Ph <sub>2</sub> SO	Ph <sub>2</sub> SO	25/0.5			<sup>e</sup>

<sup>a</sup>8-MQO = 8-methylquinoline *N*-oxide, IPr = 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene, L = P(*t*-Bu)<sub>2</sub>(*o*-biphenyl), [1a] = 0.05 M. <sup>b</sup>*N*-Oxide (1.2 equiv). <sup>c</sup>Product yields are reported after separation on a silica column. <sup>d</sup>This value corresponds to 8-MQO with 3.0 equiv. <sup>e</sup>Polymerization of starting 1a was observed.

and 11). We tested the reaction with Ph<sub>2</sub>SO (1.2 equiv),<sup>4</sup> which led to a polymerization of starting 1a (entry 12); the same polymerization was observed in the absence of oxides, reflecting the sensitivity of starting 1a toward an acidic gold catalyst. Only basic *N*-oxides can reduce the acidity of IPrAuNTf<sub>2</sub> to secure the stability of starting 1a.

Table 2 shows the gold-catalyzed reactions between various 3,5-dien-ynes 1b–1j with 3,5-dichloropyridine *N*-oxide, giving only cyclopentadienyl aldehydes 3b–3j, whereas competitive cyclopropyl indanones 2 were completely suppressed. In entries 1 and 4, starting 1b was prepared as a mixture of *E/Z* isomers (*E/Z* = 1.4), whereas species 1e was prepared as the *E*-isomer. Entries 1–4 show the applicability of this new oxidative


Table 2. Oxidative Cyclization with Various 3,5-Dien-1-ynes<sup>a</sup>


		
(1) 3b (0.3 h, 60%)	(2) 3c (0.3 h, 67%)	(3) 3d (0.3 h, 75%)
		
(4) 3e (0.3 h, 39%)	(5) 3f (0.3 h, 54%)	(6) 3g (0.3 h, 69%)
		
(7) 3h (0.5 h, 64%)	(8) 3i (0.3 h, 80%)	(9) 3j (0.5 h, 68%)

<sup>a</sup>IPr = 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene, L = P(*t*-Bu)<sub>2</sub>(*o*-biphenyl), [1a] = 0.05 M, *N*-oxide (1.2 equiv). Product yields are reported after separation on a silica column. 1b, *E/Z* = 1.4. 1e is *E*-isomer.



cyclization to 3,5-dien-1-ynes 1b–1e bearing various substituted alkenes; the resulting aldehydes 3b–3d were obtained in satisfactory yields (60–75%) with the exception of compound 3e that was obtained in a low yield (39%). We tested the reactions on 3,5-dien-1-ynes 1f–1h bearing a substituted cyclohexenyl bridge; the corresponding products 3f–3h were produced with 54–69% yields. This reaction was applicable also to substrate 1i bearing a cycloheptenyl bridge, giving desired product 3i in 80% yield. For an acyclic 3,5-dien-1-yne 1j, its gold-catalyzed reaction delivered cyclopentadienyl aldehyde 3j in 68% yield. Our attempted reaction on 3,5-dien-1-yne bearing a single phenyl substituent in the 6-position, unlike compound 1e, gave a complicated mixture of products.<sup>5</sup>

We examined the reaction of a benzenoid substrate 4 with 3,5-dichloropyridine *N*-oxide, which delivered cyclopropyl indanone 5 instead (eq 1). The same reaction pattern was observed using *N*-iminopyridium ylide<sup>6,7</sup> to afford cyclopropyl indanimine 6 in 80% yield (eq 2), whereas for non-benzenoid



3,5-dien-1-yne 1a, a different chemoselectivity occurred to give cyclopentadienyl imine 7a in 84% yield (eq 3). NaBH<sub>3</sub>CN-reduction of imine species 7a provided primary imine 8a in 67% yield, which was characterized by X-ray diffraction (eq 3).<sup>8</sup>


Table 3 shows the gold-catalyzed synthesis of cyclopentadienyl imines from the same 3,5-dien-1-ynes 1b–1j as in Table 2. The reaction proceeded with high chemoselectivity to afford cyclopentadienyl imines 7b–7j exclusively. For 3,5-dien-1-ynes 1b–1e bearing various trisubstituted alkenes, their resulting cyclopentadienyl imines 7b–7e were produced in 57–76% yields (entries 1–4). This iminocyclization was operable with additional 3,5-dien-1-ynes 1f–1h bearing a varied cyclohexenyl bridge, giving desired imines 7f–7h with 66–

Table 3. Scope for Gold-Catalyzed Iminocyclizations<sup>a</sup>

<sup>a</sup>IPr = 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene, L = P(*t*-Bu)<sub>2</sub>(*o*-biphenyl), [1a] = 0.05 M. *N*-oxide (1.2 equiv). Product yields are reported after separation on a silica column. **1b**, E/Z = 1.4. **1e**, E/Z = 1.0.

72% yields (entries 5–7). The reaction worked also with substrate **1i** bearing a cycloheptenyl bridge, giving the corresponding product **7i** in 75% yield (entry 8). Acyclic 3,5-dien-1-yne **1j** was also suitable for this iminocyclization, giving desired **7j** in 72% yield (entry 9).

As shown in Scheme 2, we performed a reaction with 8-methylquinoline *N*-oxide and 3,5-dichloropyridine *N*-oxide in


Scheme 2. Oxidation Properties of *N*-Oxides

equal proportions ((3,5-DCPO, 1.5 equiv, Scheme 2) and obtained desired cyclopropyl indanone **2a** together with a new product **9** in 33% and 39% yields respectively; cyclopentadienyl aldehyde **3a** was obtained in a negligible proportion. Pyranil aldehyde **9** was generated with 6- $\pi$  electrocyclic of  $\alpha$ -carbonyl aldehyde **9'** that resulted from a second oxidation of gold carbenes **C** (*vide ante*, Scheme 4).<sup>9</sup> Compound **3a** were generated in 15% yield with a decreasing loading of 8-methylquinoline *N*-oxide (1.1 equiv, entry 2). These data provide insight into the effects of two *N*-oxides, namely, that 8-methylquinoline *N*-oxide is more active than 3,5-dichloropyr-

idine *N*-oxide for the alkyne oxidation and is inactive toward the carbene oxidation.

Scheme 3 shows the deuterium labeling experiments. The treatment of deuterated **d**<sub>1</sub>-**1a** with 3-bromopyridine *N*-oxide


Scheme 3. Deuterium Labeling Experiments



(1.1 equiv) in DCE at 28 °C (0.5 h) led to a 80% conversion, giving unreacted **d**<sub>1</sub>-**1a** and cyclopropyl indanone **d**<sub>1</sub>-**2a** and cyclopentadienyl aldehyde **d**<sub>1</sub>-**3a** in 16%, 24%, and 54% recovery or yields, respectively. Notably, the deuterium contents X, Y, and Z are nearly the same (40–42%). Alternatively, the use of undeuterated **1a** and D<sub>2</sub>O (1.0 equiv) in this reaction also provided deuterated **d**<sub>1</sub>-**2a** and **d**<sub>1</sub>-**3a** with the same level of deuterium contents (58–60%). These results indicate that the loss of deuterium content of **d**<sub>1</sub>-**2a** and **d**<sub>1</sub>-**3a** is attributed to a quick equilibrium between  $\pi$ -alkyne **A** and alkynyl gold **B** (Scheme 4). This **A**/**B** equilibrium allows a quick change between **d**<sub>1</sub>-**1a** and water before the production of **d**<sub>1</sub>-**2a** and **d**<sub>1</sub>-**3a**.

Scheme 4 depicts possible mechanisms to rationalize the formation of cyclopropyl indanone **2a** and cyclopentadienyl


Scheme 4. Possible Reaction Mechanisms



aldehyde **3a**; the latter was produced with less nucleophilic *N*-oxides that attack  $\pi$ -alkyne **A** inefficiently. The deuterium labeling experiments in Scheme 3 indicate that an equilibrium<sup>10,11</sup> between  $\pi$ -alkyne **A** and alkynylgold species **B** is rapidly attained before products **2a** and **3a** are formed. *N*-Oxides are reported to catalyze this **A**/**B** equilibrium.<sup>10</sup>

Besides a prior cyclization route (path a) involving the transformation  $\pi$ -alkyne **A**  $\rightarrow$  gold carbene **C**, a small portion of species **B** might undergo protonation at the dienyl C(3)-carbon to give an allylic cation **D** (path b), which induces a cyclization to generate gold allenyldiene **E**, ultimately giving gold carbene **C**. We sought suitable experiments to probe the feasibility of the two paths (a and b).

We assessed the role of alkynylgold intermediate **B** to participate the alkyne oxidation, as depicted in path b. As depicted in Table 4, we prepared alkynylgold species **10**<sup>12</sup> and


Table 4. Alkynylgold Species as the Catalysts<sup>a</sup>


entry	oxidant	mol % HNTf <sub>2</sub>	min	yield <sup>b</sup>
1	Z = NTs	1.0	20	7a (86%)
2	Z = NTs	0	600	7a (56%)
3	Z = O	1.0	120	3a (75%)
4	Z = O	0	600	1a (55%)


<sup>a</sup>[1a] = 0.05 M. *N*-oxide (1.2 equiv). <sup>b</sup>Product yields are reported after separation on a silica column.

used it as a catalyst (5 mol %) in both oxidation and nitrene reactions. In the nitrene reaction, we obtained excellent yields (86%) for desired product 7a with HNTf<sub>2</sub> (1 mol %). To our surprise, the catalytic reaction still proceeded in the absence of HNTf<sub>2</sub> to give compound 7a in 56% yield over a protracted period (10 h, entry 2). In contrast, HNTf<sub>2</sub> was required for the oxidation reactions using alkynylgold 10 catalyst (entries 3 and 4).

To understand the role of alkynylgold species B in path b, we performed a control experiment in eq 4, involving 1a (1 equiv),



*N*-iminopyridium ylide (1 equiv) and alkynylgold species 11 (0.15 equiv). Heating this mixture in hot DCE for a brief period (1 h) gave no desired iminocyclization products 7a and 7f, but we obtained a mixture of 3,5-dien-1-yne 1a and 1f with a 1a/1f ratio of 7.7/1. Accordingly, alkynylgold species B preferably underwent protonation to produce gold- $\pi$ -alkyne species A, rather than giving gold-vinylidene E, thus excluding the route b in Scheme 4. Herein, *N*-iminopyridium ylide serves as a proton shuttle with dien-1-yne 1a as the proton source. At a protracted period (16 h), the same reaction gave desired iminocyclization products 7a and 7f, albeit in low yields (30–35%); in this case, alkyneamide 12 was obtained in minor proportion (eq 5). This



result reveals that alkynylgold species 11 was a poor catalyst for this iminocyclization; the corresponding mechanism might be different. The isolation of alkyneamide 12 allows us to understand the reaction mechanism in eq 4.<sup>13</sup>

## CONCLUSIONS

A distinct chemoselectivity in the gold-catalyzed oxidative cyclization of 3,5-dien-1-yne occurred when 8-methylquinoline *N*-oxide was replaced with 3,5-dichloropyridine *N*-oxide; the resulting cyclopentadienyl aldehydes were obtained in

satisfactory yields. The change of chemoselectivity is attributed to the weak nucleophilicity of 3,5-dichloropyridine *N*-oxide such that a prior cyclization of 3,5-dien-1-yne occurs preferably. The reactions were extensible to their iminocyclizations when the same 3,5-dien-1-yne were treated with *N*-iminopyridium ylide. Our experimental results support a prior gold-catalyzed cyclization of 3,5-dien-1-yne to form gold carbene C, followed by the oxidation with *N*-oxide.<sup>14</sup> In a case involving alkynylgold as the catalyst, a prior protonation of alkynylgold to give  $\pi$ -alkyne occurred preferably.

## EXPERIMENTAL SECTION

**General Comments.** Unless otherwise noted, all reactions to prepare the substrates were performed in oven-dried glassware under a nitrogen atmosphere with freshly distilled solvents. The catalytic reactions were performed under a nitrogen atmosphere. Toluene, DCE, and methanol were distilled from CaH<sub>2</sub> under nitrogen. Methanol and triethylamine (Et<sub>3</sub>N) were stored over molecular sieves (4 Å) before use. All other commercial reagents were used without further purification, unless otherwise indicated. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on 400 and 600 MHz spectrometers using chloroform-*d*<sub>1</sub> (CDCl<sub>3</sub>), CD<sub>2</sub>Cl<sub>2</sub>, or DMSO-*d*<sub>6</sub> as the internal standard. EI/MS-MS, ESI/FTMS, and ESI/orbitrap mass spectrometry were used for the HRMS measurements. All 1,5-enynes (1a–1i) were prepared from the reported procedure in the literature.<sup>15</sup>

**General Procedure for Gold-Catalyzed Oxidative Cyclization between 1,5-Enyne (1a) and 3,5-Dichloropyridine *N*-Oxide.** A 1,2-dichloroethane solution (4.2 mL) of compound 1a (50 mg, 0.31 mmol) and 3,5-dichloropyridine *N*-oxide (60.7 mg, 0.37 mmol) was added to a 1,2-dichloroethane solution (2.0 mL) of IPrAuNTf<sub>2</sub> (13.9 mg, 0.016 mmol). The mixture was heated to 80 °C for 0.5 h before it was filtered over a short silica bed. The solvent was evaporated under reduced pressure; the crude product was eluted through a silica gel column to afford 3a as a yellow oil (45.4 mg, 0.26 mmol, 83%).

**General Procedure for Gold-Catalyzed Oxidative Cyclization between 1,5-Enyne (1a) and (3,5-Dichloro-pyridinium-1-yl)-tosylamide.** To a 1,2-dichloroethane solution (4.2 mL) of compound 1a (50 mg, 0.31 mmol) and (3,5-dichloro-pyridinium-1-yl)tosylamide (117.4 mg, 0.37 mmol) was added a 1,2-dichloroethane solution (2.0 mL) of IPrAuNTf<sub>2</sub> (13.9 mg, 0.016 mmol); the mixture was heated to 80 °C for 0.5 h before it was filtered over a short silica bed. The solvent was evaporated under reduced pressure; the crude product was eluted through a silica column to afford 7a as an orange red oil (85.8 mg, 0.26 mmol, 84%).

**Procedure for Gold-Catalyzed Oxidative Cyclization between Deuterated 1-Ethynyl-2-(2-methylprop-1-en-1-yl)-cyclohex-1-ene (*d*<sub>1</sub>-1a) and 3-Bromo Pyridine *N*-Oxide.** A 1,2-dichloroethane solution (3.7 mL) of compound *d*<sub>1</sub>-1a (50 mg, 0.31 mmol) and 3-bromopyridine *N*-oxide (64.4 mg, 0.37 mmol) was added to a 1,2-dichloroethane solution (2.5 mL) of IPrAuNTf<sub>2</sub> (13.8 mg, 0.016 mmol). The mixture was heated to 80 °C for 0.5 h before it was filtered over a short silica bed. The solvent was evaporated under reduced pressure; the crude product was eluted through a silica gel column to afford compound *d*<sub>1</sub>-1a as a pale yellow oil (8.0 mg, 0.05 mol, 16%), compound *d*<sub>1</sub>-2a as a colorless oil (13.2 mg, 0.07 mmol, 24%), and compound *d*<sub>1</sub>-3a as a yellow oil (29.7 mg, 0.17 mmol, 54%).

**Synthesis of *N*-(2,2-Dimethyl-4,5,6,7-tetrahydro-2*H*-inden-1-yl)methyl)-4-methylbenzenesulfonamide (8a).** To a THF solution (5.2 mL) of compound 7a (86 mg, 0.26 mmol) was added NaBH<sub>3</sub>CN (18 mg, 0.26 mmol), and the mixture was stirred for 4 h at room temperature, quenched with water, and extracted with ethyl acetate (20 mL × 3). The combined organic layer was dried over anhydrous MgSO<sub>4</sub> and concentrated on an evaporator. The residue was eluted through a short pad of silica column to afford compound 8a as pale yellow solid (58 mg, 0.17 mmol, 67%).

**Synthesis of 3,3-Dimethyl-5,6,7,8-tetrahydro-3*H*-isochromene-1-carbaldehyde (9).** A 1,2-dichloroethane solution (3.7 mL) of compound 1a (50 mg, 0.31 mmol), 8-methylquinoline *N*-oxide (74.8 mg, 0.47 mmol), and 3,5-dichloropyridine *N*-oxide (152.5

mg, 0.93 mmol) was added to a 1,2-dichloroethane solution (2.5 mL) of IPrAuNTf<sub>2</sub> (13.8 mg, 0.016 mmol). The mixture was heated to 80 °C for 0.5 h before it was filtered over a short silica bed. The solvent was evaporated under reduced pressure; the crude product was eluted through a silica gel column to afford compound **2a** as a pale yellow oil (18 mg, 0.10 mol, 33%), compound **9** as a yellow oil (23.0 mg, 0.12 mmol, 39%), and a trace amount of compound **3a** with yellow oil.

**Synthesis of 1,3-Bis(2,6-diisopropylphenyl)imidazol-2-ylidene((2-(2-methylprop-1-en-1-yl)cyclohex-1-en-1-yl)ethynyl)gold (10).** A round-bottom flask (10 mL) was charged with 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene gold chloride (76.7 mg, 0.12 mmol) and NaOH (9.6 mg, 0.24 mmol). After the flask was evacuated and refilled with nitrogen, methanol (3.0 mL) was added by syringe, and the reaction mixture was stirred for 20 min. Dichloromethane (1.5 mL) was added until a homogeneous solution was obtained. Compound **1a** (20.0 mg, 0.12 mmol) was added directly to this solution. The reaction was covered in foil and stirred for 36 h followed by removal of the volatiles under vacuum and extraction of the residue with benzene (10 mL × 3). After filtration to remove insoluble salts and purification by recrystallization (benzene and pentane), the desired compound **10** was obtained as white solid (61.0 mg, 0.082 mmol, 68%).

**Synthesis of 1,3-Bis(2,6-diisopropylphenyl)imidazol-2-ylidene((5,5-dimethyl-2-(2-methylprop-en-1-yl)cyclohex-1-en-1-yl)ethynyl)gold (11).** A MeOH solution (4.2 mL) of NaO<sup>t</sup>Bu (15.4 mg, 0.16 mmol) and compound **1f** (30.0 mg, 0.16 mmol) was stirred for 10 min before addition of a MeOH solution (2.0 mL) of 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene gold chloride (49.7 mg, 0.08 mmol). The reaction was covered in foil and stirred for 48 h followed by removal of the volatiles under vacuum and extraction of the residue with dichloromethane (10 mL × 3). After filtration to remove insoluble salts and purification by recrystallization (benzene and pentane), the desired compound **11** was obtained as a pale yellow solid (84.0 mg, 0.11 mmol, 68%).

**Synthesis of (3,5-Dichloropyridin-1-ium-1-yl)((2-(2-methylprop-1-en-1-yl)cyclohex-1-en-1-yl)ethynyl)amide (12).** To a 1,2-dichloroethane solution (4.2 mL) of compound **1a** (50 mg, 0.31 mmol) and (3,5-dichloropyridinium-1-yl)tosylamide (104.7 mg, 0.33 mmol) was added a 1,2-dichloroethane solution (2.0 mL) of compound **11** (36.0 mg, 0.047 mmol); the mixture was heated to 80 °C for 1 h before it was filtered over a short silica bed. The solvent was evaporated under reduced pressure; the crude product was eluted through a silica column to afford compound **1a** as a yellow oil (42 mg, 0.26 mmol, 85%), compound **1f** as a yellow oil (6.5 mg, 0.034 mmol, 0.11 equiv), and compound **12** as a yellow oil (7.0 mg, 0.022 mmol, 0.07 equiv).

**Deuterated 1,1-Dimethyl-1,2,3,4,5,6a-hexahydrocyclopropa[*a*]inden-6(1*a*H)-one (d<sub>1</sub>-2a).** Pale yellow oil; (13 mg, 24%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.40–2.34 (m, 1 H), 2.17–2.11 (m, 2 H), 2.10–2.03 (m, 2 H), 1.92 (d, *J* = 4.4 Hz, 0.6 H), 1.70–1.61 (m, 3 H), 1.52–1.48 (m, 1 H), 1.17 (s, 3 H), 1.04 (s, 3 H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 204.3, 168.8, 137.3, 48.3, 48.2, 38.1, 37.9 (t, *J* = 26 Hz), 37.3, 37.2, 28.7, 27.2, 27.1, 22.2, 21.7, 19.5, 14.3; HRMS calcd for C<sub>12</sub>H<sub>16</sub>O 176.1201, found 176.1197, 177.1262.

**2,2-Dimethyl-4,5,6,7-tetrahydro-2*H*-indene-1-carbaldehyde (3a).** Yellow oil; (45 mg, 83%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.86 (s, 1 H), 6.28 (s, 1 H), 2.86 (t, *J* = 6.4 Hz, 2 H), 2.47 (td, *J* = 6.4, 2.0 Hz, 2 H), 1.72–1.59 (m, 4 H), 1.21 (s, 6 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 183.8, 160.6, 151.1, 145.5, 139.3, 51.1, 24.8, 24.0, 22.8, 22.4, 21.8; HRMS calcd for C<sub>12</sub>H<sub>16</sub>O 176.1201, found 176.1195.

**Deuterated 2,2-Dimethyl-4,5,6,7-tetrahydro-2*H*-indene-1-carbaldehyde (d<sub>1</sub>-3a).** Pale yellow oil; (30 mg, 54%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.87 (s, 0.58 H), 6.29 (s, 1 H), 2.87 (t, *J* = 6.0 Hz, 2 H), 2.47 (t, *J* = 5.6 Hz, 2 H), 1.72–1.63 (m, 4 H), 1.22 (s, 6 H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 183.8, 183.5 (t, *J* = 102 Hz), 160.6, 151.1, 145.4, 139.3, 51.1, 24.7, 24.0, 22.8, 22.4, 21.8; HRMS calcd for C<sub>12</sub>H<sub>16</sub>O 176.1201, found 176.1206, 177.1268.

**2-Ethyl-2-methyl-4,5,6,7-tetrahydro-2*H*-indene-1-carbaldehyde (3b).** Yellow oil; (36 mg, 60%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.85 (s, 1 H), 6.27 (s, 1 H), 2.88 (t, *J* = 5.6 Hz, 2 H), 2.48 (t, *J* = 5.2 Hz, 2 H), 1.78 (q, *J* = 7.2 Hz, 2 H), 1.71–1.64 (m, 4 H), 1.21 (s, 3 H),

0.57 (td, *J* = 7.2 Hz, 0.8 Hz, 3 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 183.7, 161.8, 149.2, 144.4, 140.6, 55.5, 28.8, 24.7, 24.0, 22.9, 22.5, 20.6, 9.4; HRMS calcd for C<sub>13</sub>H<sub>18</sub>O 190.1358, found 190.1364.

**4',5',6',7'-Tetrahydrospiro[cyclopentane-1,2'-indene]-1'-carbaldehyde (3c).** Yellow oil; (36 mg, 67%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.85 (s, 1 H), 6.50 (s, 1 H), 2.87 (t, *J* = 6.0 Hz, 2 H), 2.46 (t, *J* = 6.0 Hz, 2 H), 2.20–2.13 (m, 2 H), 1.98–1.93 (m, 2 H), 1.80–1.62 (m, 6 H), 1.45–1.41 (m, 2 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 183.7, 161.6, 148.4, 142.7, 139.0, 61.7, 32.4, 26.2, 24.8, 24.1, 22.9, 22.4; HRMS calcd for C<sub>14</sub>H<sub>18</sub>O 202.1358, found 202.1350.

**4',5',6',7'-Tetrahydrospiro[cyclohexane-1,2'-indene]-1'-carbaldehyde (3d).** Pale yellow solid; (40 mg, 75%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.84 (s, 1 H), 6.92 (s, 1 H), 2.84 (t, *J* = 6.0 Hz, 2 H), 2.47 (t, *J* = 5.6 Hz, 2 H), 2.15 (td, *J* = 12.8, 3.2 Hz, 2 H), 1.76–1.61 (m, 6 H), 1.48–1.33 (m, 4 H), 1.05–1.02 (m, 2 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 184.0, 160.7, 146.8, 145.6, 140.8, 56.1, 31.4, 25.6, 25.0, 24.9, 24.1, 22.8, 22.4; HRMS calcd for C<sub>15</sub>H<sub>20</sub>O 216.1514, found 216.1512.

**2-Methyl-2-phenyl-4,5,6,7-tetrahydro-2*H*-indene-1-carbaldehyde (3e).** Yellow oil; (29 mg, 39%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.85 (s, 1 H), 7.23–7.12 (m, 5 H), 6.44 (s, 1 H), 3.03–2.88 (m, 2 H), 2.54–2.52 (m, 2 H), 1.78–1.68 (m, 4 H), 1.65 (s, 3 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 183.6, 161.6, 150.2, 146.0, 140.2, 139.9, 128.2, 126.3, 125.9, 57.6, 24.7, 24.3, 22.8, 22.4, 20.1; HRMS calcd for C<sub>17</sub>H<sub>18</sub>O 238.1358, found 238.1355.

**2,2,6,6-Tetramethyl-4,5,6,7-tetrahydro-2*H*-indene-1-carbaldehyde (3f).** Yellow oil; (29 mg, 54%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.83 (s, 1 H), 6.31 (s, 1 H), 2.60 (s, 2 H), 2.50 (td, *J* = 6.8, 1.2 Hz, 2 H), 1.49 (t, *J* = 6.8 Hz, 2 H), 1.21 (s, 6 H), 0.96 (s, 6 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 183.8, 160.9, 151.3, 146.1, 138.0, 51.7, 37.7, 35.4, 29.8, 28.0, 21.9, 20.8; HRMS calcd for C<sub>14</sub>H<sub>20</sub>O 204.1514, found 204.1507.

**5-(tert-Butyl)-2,2-dimethyl-4,5,6,7-tetrahydro-2*H*-indene-1-carbaldehyde (3g).** Yellow oil; (37 mg, 69%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.84 (s, 1 H), 6.28 (s, 1 H), 3.21 (ddd, *J* = 18.4, 4.4, 2.4 Hz, 1 H), 2.68–2.62 (m, 1 H), 2.53 (ddd, *J* = 18.4, 12.4, 5.2 Hz, 1 H), 2.07 (ddd, *J* = 16.4, 12.4, 2.4 Hz, 1 H), 1.98–1.92 (m, 1 H), 1.28 (ddd, *J* = 12.4, 4.4, 1.6 Hz, 1 H), 1.31 (s, 3 H), 1.20–1.16 (m, 4 H), 0.89 (s, 9 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 183.8, 160.7, 151.3, 145.0, 140.5, 51.5, 45.1, 32.4, 27.2, 26.2, 24.5, 24.1, 21.8 (2 × CH<sub>3</sub>); HRMS calcd for C<sub>16</sub>H<sub>24</sub>O 232.1827, found 232.1815.

**2,2-Dimethyl-4,5-dihydro-2*H*-cyclopenta[*a*]naphthalene-1-carbaldehyde (3h).** Yellow oil; (35 mg, 64%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.20 (s, 1 H), 7.69 (dd, *J* = 6.0, 2.0 Hz, 1 H), 7.37–7.33 (m, 1 H), 7.31–7.28 (m, 2 H), 6.38 (s, 1 H), 2.84 (t, *J* = 6.0 Hz, 2 H), 2.59–2.55 (m, 2 H), 1.35 (s, 6 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 185.9, 153.0, 148.2, 144.9, 140.8, 140.2, 130.2, 130.0 (2 × CH), 128.9, 126.9, 52.8, 30.6, 23.8, 22.4; HRMS calcd for C<sub>16</sub>H<sub>16</sub>O 224.1201, found 224.1198.

**2,2-Dimethyl-2,4,5,6,7,8-hexahydroazulene-1-carbaldehyde (3i).** Yellow oil; (44 mg, 80%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.86 (s, 1 H), 6.24 (s, 1 H), 2.77 (br, 2 H), 2.41–2.39 (m, 2 H), 1.72–1.70 (m, 2 H), 1.65–1.62 (m, 2 H), 1.57–1.54 (m, 2 H), 1.20 (s, 6 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 184.0, 165.5, 151.2, 146.0, 145.4, 50.8, 32.2, 30.1, 29.4, 28.7, 27.0, 21.8; HRMS calcd for C<sub>13</sub>H<sub>18</sub>O 190.1358, found 190.1361.

**3,5,5-Trimethyl-2-phenylcyclopenta-1,3-dienecarbaldehyde (3j).** Yellow oil; (37 mg, 68%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.49 (s, 1 H), 7.42–7.39 (m, 3 H), 7.30–7.28 (m), 6.43 (s, 1 H), 1.85 (s, 3 H), 1.32 (s, 6 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 187.0, 162.4, 152.6, 148.6, 138.0, 133.0, 129.3, 128.6, 128.2, 51.0, 21.7, 13.8; HRMS calcd for C<sub>15</sub>H<sub>16</sub>O 212.1201, found 212.1205.

**N-((2,2-Dimethyl-4,5,6,7-tetrahydro-2*H*-inden-1-yl)methylene)-4-methylbenzenesulfonamide (7a).** Orange red oil; (86 mg, 84%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.79 (s, 1 H), 7.81 (d, *J* = 8.4 Hz, 2 H), 7.27 (d, *J* = 8.4 Hz, 2 H), 6.45 (s, 1 H), 2.79 (t, *J* = 6.0 Hz, 2 H), 2.46 (t, *J* = 5.6 Hz, 2 H), 2.39 (s, 3 H), 1.73–1.63 (m, 4 H), 1.19 (s, 6 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 165.4, 158.8, 154.4, 143.3, 142.1, 140.2, 137.2, 129.4, 127.2, 51.6, 24.8, 24.5, 22.7, 22.2, 21.9, 21.5; HRMS calcd for C<sub>19</sub>H<sub>23</sub>NO<sub>2</sub>S 329.1449, found 329.1447.

***N*-((2-Ethyl-2-methyl-4,5,6,7-tetrahydro-2*H*-inden-1-yl)methylene)-4-methylbenzenesulfonamide (7b).** Orange red oil; (61 mg, 57%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.78 (s, 1H), 7.80 (d,  $J$  = 8.4 Hz, 2H), 7.26 (d,  $J$  = 8.4 Hz, 2H), 6.43 (s, 1H), 2.80 (t,  $J$  = 6.4 Hz, 2H), 2.47 (t,  $J$  = 6.4 Hz, 2H), 2.39 (s, 3H), 1.78 (q,  $J$  = 7.2 Hz, 2H), 1.71–1.65 (m, 4H), 1.17 (s, 3H), 0.46 (t,  $J$  = 7.2 Hz, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  166.6, 158.9, 152.7, 143.3, 141.6, 140.9, 137.2, 129.4, 127.1, 56.1, 28.9, 24.8, 24.5, 22.7, 22.2, 21.5, 20.8, 9.2; HRMS calcd for  $\text{C}_{20}\text{H}_{25}\text{NO}_2\text{S}$  343.1606, found 343.1608.

**4-Methyl-*N*-((4',5',6',7'-tetrahydrospiro[cyclopentane-1,2'-inden]-1'-yl)methylene)benzenesulfonamide (7c).** Orange red oil; (72 mg, 65%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.78 (s, 1H), 7.80 (d,  $J$  = 8.4 Hz, 2H), 7.26 (d,  $J$  = 8.4 Hz, 2H), 6.67 (s, 1H), 2.81 (t,  $J$  = 6.0 Hz, 2H), 2.46 (t,  $J$  = 5.6 Hz, 2H), 2.39 (s, 3H), 2.19–2.12 (m, 2H), 1.98–1.90 (m, 2H), 1.75–1.65 (m, 6H), 1.42–1.37 (m, 2H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  166.4, 158.7, 152.1, 143.3, 140.0, 139.5, 137.3, 129.4, 127.2, 62.1, 32.8, 26.2, 24.9, 24.6, 22.8, 22.2, 21.5; HRMS calcd for  $\text{C}_{21}\text{H}_{25}\text{NO}_2\text{S}$  355.1606, found 355.1607.

**4-Methyl-*N*-((4',5',6',7'-tetrahydrospiro[cyclohexane-1,2'-inden]-1'-yl)methylene)benzenesulfonamide (7d).** Orange red oil; (88 mg, 76%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.77 (s, 1H), 7.81 (d,  $J$  = 7.6 Hz, 2H), 7.28 (d,  $J$  = 7.6 Hz, 2H), 7.09 (s, 1H), 2.78 (t,  $J$  = 6.0 Hz, 2H), 2.48 (t,  $J$  = 6.0 Hz, 2H), 2.40 (s, 3H), 2.20 (td,  $J$  = 13.2 Hz, 3.2 Hz, 2H), 1.76–1.65 (m, 6H), 1.48–1.30 (m, 4H), 0.98 (d,  $J$  = 13.2 Hz, 2H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  165.1, 159.1, 150.6, 143.3, 142.3, 141.7, 137.1, 129.4, 127.2, 56.7, 31.5, 25.5, 24.9, 24.8, 24.7, 22.7, 22.2, 21.5; HRMS calcd for  $\text{C}_{22}\text{H}_{27}\text{NO}_2\text{S}$  369.1762, found 369.1770.

**4-Methyl-*N*-((2-methyl-2-phenyl-4,5,6,7-tetrahydro-2*H*-inden-1-yl)methylene)benzenesulfonamide (7e).** Orange red oil; (78 mg, 64%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.75 (s, 1H), 7.43 (d,  $J$  = 8.4 Hz, 2H), 7.11 (d,  $J$  = 8.4 Hz, 2H), 7.08–7.07 (m, 3H), 7.03–7.01 (m, 2H), 6.58 (s, 1H), 2.95–2.80 (m, 2H), 2.54–2.52 (m, 2H), 2.35 (s, 3H), 1.75–1.69 (m, 4H), 1.67 (s, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  166.2, 159.0, 153.2, 143.2, 142.9, 141.1, 139.3, 137.2, 129.1, 128.0, 126.7, 126.2, 126.1, 58.1, 25.1, 24.6, 22.7, 22.2, 21.4, 20.0; HRMS (ESI (+))  $\text{C}_{24}\text{H}_{25}\text{NO}_2\text{S}$ , calcd 391.1606 [M], found 391.1606.

**4-Methyl-*N*-((2,2,6,6-tetramethyl-4,5,6,7-tetrahydro-2*H*-inden-1-yl)methylene)benzenesulfonamide (7f).** Orange red oil; (78 mg, 70%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.79 (s, 1H), 7.83 (d,  $J$  = 8.0 Hz, 2H), 7.27 (d,  $J$  = 8.0 Hz, 2H), 6.48 (s, 1H), 2.54 (s, 2H), 2.51 (t,  $J$  = 6.8 Hz, 2H), 2.40 (s, 3H), 1.50 (t,  $J$  = 6.8 Hz, 2H), 1.19 (s, 6H), 0.96 (s, 6H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  165.9, 158.8, 154.7, 143.3, 142.7, 138.9, 137.4, 129.4, 127.2, 52.2, 38.4, 35.3, 29.9, 27.9, 22.0, 21.5, 20.7; HRMS calcd for  $\text{C}_{21}\text{H}_{27}\text{NO}_2\text{S}$  357.1762, found 357.1761.

***N*-((5-(*tert*-Butyl)-2,2-dimethyl-4,5,6,7-tetrahydro-2*H*-inden-1-yl)methylene)-4-methylbenzenesulfonamide (7g).** Orange red oil; (87 mg, 72%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.78 (s, 1H), 7.82 (d,  $J$  = 8.0 Hz, 2H), 7.27 (d,  $J$  = 8.0 Hz, 2H), 6.46 (s, 1H), 3.14–3.09 (m, 1H), 2.67–2.63 (m, 1H), 2.54–2.45 (m, 1H), 2.40 (s, 3H), 2.12–2.05 (m, 1H), 2.01–1.97 (m, 1H), 1.36–1.27 (m, 2H), 1.20 (s, 3H), 1.18 (s, 3H), 0.90 (s, 9H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  165.5, 158.8, 154.6, 143.3, 141.7, 141.4, 137.2, 129.4, 127.2, 52.0, 45.0, 32.4, 27.2, 26.0, 25.3, 23.8, 22.0, 21.9, 21.5; HRMS calcd for  $\text{C}_{23}\text{H}_{31}\text{NO}_2\text{S}$  385.2075, found 385.2070.

***N*-((2,2-Dimethyl-4,5-dihydro-2*H*-cyclopenta[*a*]naphthalene-1-yl)methylene)-4-methylbenzenesulfonamide (7h).** Orange red oil; (78 mg, 66%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.16 (s, 1H), 7.84 (d,  $J$  = 8.4 Hz, 2H), 7.56 (d,  $J$  = 7.2 Hz, 1H), 7.38–7.33 (m, 2H), 7.31–7.28 (m, 3H), 6.50 (s, 1H), 2.82 (t,  $J$  = 6.0 Hz, 2H), 2.59–2.55 (m, 2H), 2.41 (s, 3H), 1.31 (s, 6H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  161.4, 157.0, 151.0, 143.5, 141.0, 140.8 (2  $\times$  C), 136.8, 130.5, 130.1, 129.5, 129.4, 129.0, 127.4 (2  $\times$  CH), 53.2, 30.4, 23.7, 22.5, 21.5; HRMS calcd for  $\text{C}_{23}\text{H}_{23}\text{NO}_2\text{S}$  377.1449, found 377.1447.

***N*-((2,2-Dimethyl-2,4,5,6,7,8-hexahydroazulen-1-yl)methylene)-4-methylbenzenesulfonamide (7i).** Orange red oil; (80 mg, 75%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.86 (s, 1H), 7.82 (d,  $J$  = 8.4 Hz, 2H), 7.27 (d,  $J$  = 8.4 Hz, 2H), 6.41 (s, 1H), 2.73–2.71 (m, 2H), 2.44–2.41 (m, 2H), 2.40 (s, 3H), 1.75–1.72 (m, 2H), 1.64–1.63

(m, 2H), 1.57–1.55 (m, 2H), 1.19 (s, 6H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  170.3, 159.3, 154.3, 146.0, 143.3, 142.3, 137.2, 129.4, 127.2, 51.2, 32.1, 30.0, 29.2, 28.5, 28.1, 21.9, 21.5; HRMS calcd for  $\text{C}_{20}\text{H}_{25}\text{NO}_2\text{S}$  343.1606, found 343.1609.

**4-Methyl-*N*-((3,5,5-trimethyl-2-phenylcyclopenta-1,3-dien-1-yl)methylene)benzenesulfonamide (7j).** Orange red solid; (82 mg, 72%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.47 (s, 1H), 7.77 (d,  $J$  = 8.4 Hz, 2H), 7.43–7.42 (m, 3H), 7.26 (d,  $J$  = 8.4 Hz, 2H), 7.20–7.18 (m, 2H), 6.56 (s, 1H), 2.39 (s, 3H), 1.87 (s, 3H), 1.29 (s, 6H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  166.1, 162.0, 155.6, 145.0, 143.5, 138.7, 136.6, 132.7, 129.4, 129.0 (2  $\times$  CH), 128.5, 127.4, 51.5, 21.9, 21.5, 13.9; HRMS calcd for  $\text{C}_{22}\text{H}_{23}\text{NO}_2\text{S}$  365.1449, found 365.1444.

***N*-((2,2-Dimethyl-4,5,6,7-tetrahydro-2*H*-inden-1-yl)methyl)-4-methylbenzenesulfonamide (8a).** Pale yellow solid; (58 mg, 67%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.76 (d,  $J$  = 8.4 Hz, 2H), 7.31 (d,  $J$  = 8.4 Hz, 2H), 5.73 (s, 1H), 3.97 (br, 1H), 3.65 (d,  $J$  = 5.2 Hz, 2H), 2.43 (s, 3H), 2.35–2.34 (m, 2H), 2.18 (br, 2H), 1.53–1.51 (m, 4H), 0.98 (s, 6H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  143.3, 140.2, 139.5, 138.4, 136.5, 129.6 (2  $\times$  CH), 127.2, 51.5, 37.8, 25.3, 23.5, 23.4, 23.2, 22.2, 21.5; HRMS calcd for  $\text{C}_{19}\text{H}_{25}\text{NO}_2\text{S}$  331.1606, found 331.1602.

**3,3-Dimethyl-5,6,7,8-tetrahydro-3*H*-isochromene-1-carbaldehyde (9).** Yellow oil; (23 mg, 39%);  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.78 (s, 1H), 5.35 (s, 1H), 2.74 (t,  $J$  = 6.0 Hz, 2H), 2.28 (t,  $J$  = 6.0 Hz, 2H), 1.67–1.56 (m, 4H), 1.31 (s, 6H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  184.4, 149.2, 142.9, 131.1, 129.4, 75.2, 29.1, 26.7, 23.3, 23.0, 22.8; HRMS calcd for  $\text{C}_{12}\text{H}_{16}\text{O}_2$ : 192.1150, found 192.1147.

**1,3-Bis(2,6-diisopropylphenyl)imidazol-2-ylidene((2-(2-methylprop-1-en-1-yl)cyclohex-1-en-1-yl)ethynyl)gold (10).** White solid; (61 mg, 68%);  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.44 (t,  $J$  = 7.8 Hz, 2H), 7.24 (d,  $J$  = 7.8 Hz, 4H), 7.08 (s, 2H), 5.96 (s, 1H), 2.59–2.55 (m, 4H), 2.10–2.08 (m, 4H), 1.62 (s, 3H), 1.58 (s, 3H), 1.45–1.44 (m, 4H), 1.33 (d,  $J$  = 7.2 Hz, 12H), 1.18 (d,  $J$  = 7.2 Hz, 12H);  $^{13}\text{C}$  NMR (150 MHz,  $\text{CDCl}_3$ )  $\delta$  191.7, 145.7, 138.9, 134.4, 132.7, 131.6, 130.4, 127.1, 124.1, 123.0, 118.8, 105.6, 31.5, 30.0, 28.8, 27.0, 24.5, 24.0, 22.9, 22.7, 20.7; HRMS calcd for  $\text{C}_{39}\text{H}_{51}\text{AuN}_2$ : 744.3718, found 744.3712.

**1,3-Bis(2,6-diisopropylphenyl)imidazol-2-ylidene((5,5-dimethyl-2-(2-methylprop-1-en-1-yl)cyclohex-1-en-1-yl)ethynyl)gold (11).** Pale yellow solid; (84 mg, 68%);  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  7.44 (t,  $J$  = 7.8 Hz, 2H), 7.24 (d,  $J$  = 7.8 Hz, 4H), 7.08 (s, 2H), 5.95 (s, 1H), 2.59–2.55 (m, 4H), 2.10 (t,  $J$  = 6.6 Hz, 2H), 1.90 (s, 2H), 1.63 (s, 3H), 1.59 (s, 3H), 1.33 (d,  $J$  = 7.2 Hz, 12H), 1.21 (t,  $J$  = 6.6 Hz, 2H), 1.18 (d,  $J$  = 7.2 Hz, 12H), 0.78 (s, 6H);  $^{13}\text{C}$  NMR (150 MHz,  $\text{CDCl}_3$ )  $\delta$  191.7, 145.6, 137.2, 134.4, 132.9, 131.1, 130.3, 126.6, 124.1, 123.0, 118.0, 105.8, 45.1, 35.6, 28.8, 28.7, 28.0, 27.5, 27.0, 24.5, 24.0, 20.7; HRMS (ESI (+))  $\text{C}_{41}\text{H}_{56}\text{AuN}_2$ , calcd 773.4104 [M + H] $^+$ , found 773.4128.

**(3,5-Dichloropyridin-1-ium-1-yl)((2-(2-methylprop-1-en-1-yl)cyclohex-1-en-1-yl)ethynyl)amide (12).** Yellow oil; (7 mg, 7%);  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ )  $\delta$  8.32 (s, 1H), 7.05 (d,  $J$  = 1.2 Hz, 1H), 6.64 (d,  $J$  = 0.6 Hz, 1H), 5.80 (s, 1H), 2.59–2.56 (m, 2H), 2.19–2.18 (m, 2H), 1.77–1.67 (m, 7H), 1.43 (s, 3H);  $^{13}\text{C}$  NMR (150 MHz,  $\text{CDCl}_3$ )  $\delta$  156.5, 137.9, 137.3, 133.6, 126.7, 125.6, 125.1, 123.5, 123.2, 117.6, 97.7, 31.5, 28.7, 25.6, 22.9, 22.7, 19.3; HRMS calcd for  $\text{C}_{17}\text{H}_{18}\text{Cl}_2\text{N}_2$  320.0847, found 320.0854.

## ■ ASSOCIATED CONTENT

### Supporting Information

HRMS  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of compounds *d*<sub>1</sub>-2a, 3a–3j, *d*<sub>1</sub>-3a, 7a–7j, 8a, 9, 10, 11, and 12, and crystallographic data for compound 8a. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## ■ AUTHOR INFORMATION

### Corresponding Author

\*E-mail: [rsliu@mx.nthu.edu.tw](mailto:rsliu@mx.nthu.edu.tw).

## Notes


The authors declare no competing financial interest.

## ACKNOWLEDGMENTS


We thank National Science Council, Taiwan, for financial support of this work.

## REFERENCES

- (1) Review: Xiao, J.; Li, X. *Angew. Chem., Int. Ed.* **2011**, *50*, 7226.
- (2) Selected examples: (a) Lu, B.; Li, C.; Zhang, L. *J. Am. Chem. Soc.* **2011**, *132*, 14070. (b) Vasu, D.; Hung, H.-H.; Bhunia, S.; Gawade, S. A.; Das, A.; Liu, R.-S. *Angew. Chem., Int. Ed.* **2011**, *50*, 6911. (c) He, W.; Li, C.; Zhang, L. *J. Am. Chem. Soc.* **2011**, *133*, 8482. (d) Davies, P. W.; Cremonesi, A.; Martin, N. *Chem. Commun.* **2011**, *47*, 379. (e) Dateer, R.-B.; Pati, K.; Liu, R.-S. *Chem. Commun.* **2012**, *48*, 7200. (f) Bhunia, S.; Ghorpade, S.; Huple, D. B.; Liu, R.-S. *Angew. Chem., Int. Ed.* **2012**, *51*, 2939. (g) Luo, Y.; Ji, K.; Li, Y.; Zhang, L. *J. Am. Chem. Soc.* **2012**, *134*, 17412. (h) Ghorpade, S.; Su, M.-D.; Liu, R.-S. *Angew. Chem., Int. Ed.* **2013**, *52*, 4229. (i) Fu, J.; Shang, H.; Wang, Z.; Chang, L.; Shao, W.; Yang, Z.; Tang, Y. *Angew. Chem., Int. Ed.* **2013**, *52*, 4198. (j) Henrion, G.; Chavas, T. E. J.; Goff, X. L.; Gagosz, F. *Angew. Chem., Int. Ed.* **2013**, *52*, 6277. (k) Pawar, S. K.; Wang, C.-D.; Bhunia, S.; Jadhav, A. M.; Liu, R.-S. *Angew. Chem., Int. Ed.* **2013**, *52*, 7559.
- (3) For other pyridine N-oxides, see selected examples: (a) Ye, L.; Cui, L.; Zhang, G.; Zhang, L. *J. Am. Chem. Soc.* **2010**, *132*, 3258. (b) Ye, L.; He, W.; Zhang, L. *J. Am. Chem. Soc.* **2010**, *132*, 8550. (c) Ye, L.; He, W.; Zhang, L. *Angew. Chem., Int. Ed.* **2011**, *50*, 3236.
- (4) (a) Witham, C. A.; Mauleón, P.; Shapiro, N. D.; Sherry, B. D.; Toste, F. D. *J. Am. Chem. Soc.* **2007**, *129*, 5838. (b) Morimoto, T.; Fuji, K.; Tsutsumi, K.; Kakiuchi, K. *J. Am. Chem. Soc.* **2002**, *124*, 3806.
- (5) For 6-phenyl-substituted substrates, we envisage that their resulting carbene intermediates are prone to a loss of proton, giving chemically reactive fulvene products:



- (6) Li, C.; Zhang, L. *Org. Lett.* **2011**, *13*, 1738.
- (7) Hung, H.-H.; Liao, Y.-C.; Liu, R.-S. *Adv. Synth. Catal.* **2013**, *355*, 1545.
- (8) X-ray crystallographic data were deposited at Cambridge Crystallographic Data Center (CCDC 939601).
- (9) A double oxidation of terminal alkynes was reported by Hashmi and coworkers; see: Shi, S.; Wang, T.; Yang, W.; Rudolph, M.; Hashmi, A. S. K. *Chem.—Eur. J.* **2013**, *19*, 6576.
- (10) Ye, L.; Wang, Y.; Aue, D. H.; Zhang, L. *J. Am. Chem. Soc.* **2012**, *134*, 31.
- (11) (a) Hashmi, A. S. K.; Braun, I.; Nösel, P.; Schädlich, J.; Wietek, M.; Rudolph, M.; Rominger, F. *Angew. Chem., Int. Ed.* **2012**, *51*, 4456. (b) Hashmi, A. S. K.; Wietek, M.; Braun, I.; Nösel, P.; Jongbloed, L.; Rudolph, M.; Rominger, F. *Adv. Synth. Catal.* **2012**, *354*, 555. (c) Hashmi, A. S. K.; Braun, I.; Rudolph, M.; Rominger, F. *Organometallics* **2012**, *31*, 64.
- (12) Preparation of alkynylgold complexes, see: Manbeck, G. F.; Kohler, M. C.; Porter, M. R.; Stockland, R. A., Jr. *Dalton Trans.* **2011**, *40*, 12595.
- (13) We postulated a mechanism to rationalize the formation of alkynylamide species **12**, which involves a proton transfer from 3,5-dien-1-yne **1a** to *N*-iminopyridium ylide to give **G**. In this ion pair, acetylide anion is stabilized with an electron-deficient pyridine core. An attack of the acetylide of species **G** at the electrophilic NHTs terminus gives intermediate **H** that provides a proton for the demetalation of species **11**; this process is expected to give 3,5-dien-1-yne **1f** and compound **11**. We speculate that the poor activity of this reaction is caused by the presence of NTf<sub>2</sub><sup>-</sup> as a counteranion or alkynylamide **12** to inhibit the reaction.



(14) For gold-catalyzed oxidations of 1,*n*-enynes following path **a**, see ref 4a and Taduri, B. P.; Abu Sohel, S. Md.; Cheng, H.-M.; Liu, R.-S. *Chem. Commun.* **2007**, 2530.

(15) (a) Lian, J.-J.; Odedra, A.; Wu, C.-J.; Liu, R.-S. *J. Am. Chem. Soc.* **2005**, *127*, 4186. (b) Barluenga, J.; Andina, F.; Aznar, F.; Valdés, C. *Org. Lett.* **2007**, *9*, 4143.